Health
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
RAHWAY, N.J. & NUTLEY, N.J., October 28, 2025--Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/805577c9f751abce8b8bd5a721337186"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QNGW7xht.IEIHRgOtUFyJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/805577c9f751abce8b8bd5a721337186","width":480,"height":217}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":324,"url":"https://media.zenfs.com/en/business-wire.com/a0d843196021f18645444f808c5b205c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uTPvGNYHvlo290acv_LkoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a0d843196021f18645444f808c5b205c","width":480,"height":324}}},{"type":"text","content":"First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed following anti-PD-1/L1 therapy compared with cabozantinib in a Phase 3 study","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"LITESPARK-011 marks the first positive Phase 3 study of a HIF-2 alpha inhibitor in combination with a multi-targeted VEGF tyrosine kinase inhibitor","length":147,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J. & NUTLEY, N.J., October 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, met one of its primary endpoints of progression-free survival (PFS) for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-PD-1/L1 therapy.","length":675,"tagName":"p"},{"type":"text","content":"At a pre-specified interim analysis, WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in PFS compared to...